Vijay Mahant

I am Dr. Vijay Mahant, Editor-in-Chief of the Journal of Biomedical Research & Environmental Sciences under Medicine.

First of all, I would like to take this wonderful opportunity to introduce a multidisciplinary Journal of Biomedical Research & Environmental Sciences covering the fields of Medicine, Biology, General Science, and Environmental Sciences to the scientific community.

I consider it a tremendous honor to be Editor-in-Chief of the journal, the main purpose of which is to create a forum for many young people to disseminate their work internationally. I would also like to express my appreciation to the publication that I was very pleased with their services, such as the regular review process, and the swift publication of instant status to me. So, I would like to expand this invitation to all scholars, scientists, students to develop their expertise and knowledge by submitting their papers to this journal. You should share this invitation with your teammates and colleagues; co-authors are most welcome.

I look forward to the participation and contribution of scholars, practitioners, scientists, including stakeholders, on an inspiring and enriching path together towards global improvement.

Thank you very much and have a prosperous future.


Your’s sincerely,
Vijay Mahant

Vijay Mahant received his M.S., Ph.D., and first post-doctorate from LUT (UK). He received his second post-doctorate from the UT Health Science Center at Houston/MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with more than 35 years of experience in immuno-and precision medicine (oncology, cardiology, pain management and psychiatry, etc.). His work in diagnostics has included the next generation TSH assay, PSA, Pharmacogenetics, cervical cancer (Human Papilloma Virus) and infectious diseases such as TB and Respiratory Virus Panel (common flu,and a number of coronaviruses) . He held senior positions at Nicholas Institute/ Quest and executive positions at Qualigen and AGI.. He is a founder/co-founder of diagnostic companies such as MediLite. Dr. Manhunt has been involved in fund-raising (about $140 million), Initial Public Offerings (IPOs), including an acquisition. Dr. Mahant is currently the CSO of Oncology Pharma (contract will expire in October 2020). Oncology Pharma is focused on “targeted” chemos and bio-pharmaceutical based drugs “soft biopsies”, including precision oncology combined with artificial intelligence and machine learning. He is a former VP, Precision oncology, Batu Biologics (cellular antiangiogenic vaccine) and in addition, he served on SAB/MAB of Batu Biologics. Dr. Mahant is currently on the advisory board of several young biotech companies such as Trutino BioSciences (an oncology company developing IL-2 based drugs), and Immunicom (a cancer therapeutic device company) , including an oncology hospital (Chipsa) and United Cancer Center (Outpatient clinic, expected to be in operation in summer 2020) Dr. Mahant has 30 issued patents and five patents pending; he has authored and/or co-authored publications in journals and science books; he is the Section Editor for the “Echo System of Translational Medicine, Journal of Translational Medicine.

Oncology, Cardiology, Pain Management and Psychiatry